Fairdeal Pharmeco Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-11-2024
- Paid Up Capital ₹ 3.66 M
as on 15-11-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.30 Cr
as on 15-11-2024
- Revenue 11.89%
(FY 2023)
- Profit -12.78%
(FY 2023)
- Ebitda -13.30%
(FY 2023)
- Net Worth 14.99%
(FY 2023)
- Total Assets 38.49%
(FY 2023)
About Fairdeal Pharmeco
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.66 M.
The company currently has active open charges totaling ₹5.30 Cr.
Shyam Maskara, Lila Maskara, Rajesh Maskara, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230BR2006PTC012288
- Company No.
012288
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Apr 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Fairdeal Pharmeco?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shyam Maskara  | Director | 10-Apr-2006 | Current |
| Lila Maskara | Director | 10-Apr-2006 | Current |
| Rajesh Maskara | Director | 10-Apr-2006 | Current |
| Savita Maskara | Director | 10-Apr-2006 | Current |
Financial Performance of Fairdeal Pharmeco.
Fairdeal Pharmeco Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.89% increase. The company also saw a substantial fall in profitability, with a 12.78% decrease in profit. The company's net worth Soared by an impressive increase of 14.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fairdeal Pharmeco?
In 2023, Fairdeal Pharmeco had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
K.B.M. Enterprises Private LimitedActive 18 years 7 monthsShyam Maskara and Rajesh Maskara are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Jul 2020 | ₹4.00 M | Open |
Others Creation Date: 26 Dec 2017 | ₹2.50 Cr | Open |
Bank Of India Muradpur Chauhatta Branch Creation Date: 06 May 2013 | ₹4.00 M | Open |
How Many Employees Work at Fairdeal Pharmeco?
Unlock and access historical data on people associated with Fairdeal Pharmeco, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fairdeal Pharmeco, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fairdeal Pharmeco's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
